Dr. Martens (LON:DOCS) Shares Down 10.3% – What’s Next?

Dr. Martens plc (LON:DOCS)’s share price traded down 10.3% on Tuesday . The company traded as low as GBX 65 and last traded at GBX 67.88. 5,231,756 shares were traded during mid-day trading, an increase of 185% from the average session volume of 1,832,502 shares. The stock had previously closed at GBX 75.65.

Key Dr. Martens News

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Berenberg reaffirmed a “buy” rating on DOCS, which supports a constructive view from at least one broker and can provide a floor for sentiment. Berenberg Buy Reaffirmed Broker Notes on LSE
• Neutral Sentiment: Trading showed elevated volume vs. average, suggesting the move is driven by active repositioning rather than thin liquidity; keep an eye on follow-through volume and whether buy-side interest re-emerges. (Background: DOCS has a relatively high P/E and leverage that can amplify sentiment-driven moves.)
• Negative Sentiment: Management now expects flat revenue for fiscal 2026 as it scales back discounting — this signals weaker top‑line growth than investors may have hoped, even if margin benefits from fewer discounts are possible; the guidance is the primary driver of the negative market reaction. Dr Martens projects flat 2026 revenue

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Peel Hunt restated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Berenberg Bank restated a “buy” rating on shares of Dr. Martens in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Stock Down 11.6%

The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The stock’s 50-day moving average price is GBX 76.53 and its 200-day moving average price is GBX 83.47. The company has a market cap of £646.63 million, a P/E ratio of 39.35, a PEG ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last released its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. As a group, research analysts forecast that Dr. Martens plc will post 2.5809394 EPS for the current year.

Insider Buying and Selling

In other news, insider Robert Hanson acquired 96,000 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were purchased at an average cost of GBX 79 per share, for a total transaction of £75,840. Insiders have purchased 97,130 shares of company stock worth $7,673,816 over the last three months. 2.79% of the stock is currently owned by corporate insiders.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.